Results 131 to 140 of about 585,966 (213)

Skin and Soft Tissue Mucormycosis in Patients Receiving Bruton Tyrosine Kinase Inhibitors: Case Report and Literature Review. [PDF]

Open Forum Infect Dis
Aparicio-Minguijón E, López-Muñoz N, Boán J, Pérez-Jacoiste Asín MA, de la Serna J, Pérez-Ayala A, Enguita AB, Rodríguez-Goncer I, Fernández-Ruiz M.   +8 more
europepmc   +1 more source

Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents. [PDF]

Am J Cardiovasc Drugs
Spadafora L, Russo F, Bukowska-Olech E, Panichella G, Garofalo M, Cacciatore S, Sabouret P, Sarto G, Simeone B, Rocco E, Lauretti A, Versaci F, Zoccai GB, Colaiori I, Valenti V, Sciarretta S, Bernardi M.   +16 more
europepmc   +1 more source

Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease-Driving Inflammation While Promoting Regulatory B Cells. [PDF]

Neurol Neuroimmunol Neuroinflamm
Dybowski S, Thode J, Freier M, Saberi D, Nessler S, Geladaris A, Häusser-Kinzel S, Ringelstein M, Torke S, Weber MS.   +9 more
europepmc   +1 more source

Bruton tyrosine kinase inhibitors and invasive aspergillosis and mucormycosis: a case report and multi-center exploratory retrospective study. [PDF]

ASM Case Rep
Bhaimia E, Russell D, Santos CAQ.
europepmc   +1 more source

BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia. [PDF]

J Clin Oncol
Davids MS.
europepmc   +1 more source

Bruton Tyrosine Kinase in Lesions of Multiple Sclerosis and 3 of Its Models. [PDF]

Neurol Neuroimmunol Neuroinflamm
Li C, Morch MT, Gorter R, Lozinski B, Ghorbani S, Dong Y, Shen YA, Harp C, Zandee S, Klement W, Prat A, Yong VW.   +11 more
europepmc   +1 more source

Real-world efficacy of Bruton tyrosine kinase inhibitor based maintenance therapy in diffuse large B-cell lymphoma: a multicenter retrospective cohort study with external historical control. [PDF]

Cancer Biol Ther
Lyu LW, Yao N, Liu ZX, Wang YY, Li J, Zhou HB, Li LH, Li ZL, Wang L.   +8 more
europepmc   +1 more source

Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors. [PDF]

Blood Res
Hur JY, Lee JH, Lee JH, Park HS, Park H, Choi Y, Choi JH, Won YW, Yoon SE, Kim WS, Kim SJ.   +10 more
europepmc   +1 more source

An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors. [PDF]

ACS Pharmacol Transl Sci
Corrionero A, Zhang X, Alfonso P, Morris PJ, Klumpp-Thomas C, Melani C, McKnight C, Phelan JD, Holland D, Wilson K, Hoyt SB, Roschewski M, Tonge PJ, Wilson W, Ceribelli M, Staudt LM, Thomas CJ.   +16 more
europepmc   +1 more source